Literature DB >> 29174186

Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.

Alexandre de Nonneville1, Renaud Sabatier2, Anthony Gonçalves2, Jean-Marc Extra3, Carole Tarpin3, Simon Launay2, Louis Tassy3, Patrice Viens2, Frederique Rousseau3.   

Abstract

Entities:  

Keywords:  Elderly; Eribulin; Metastatic breast cancer; Toxicity

Mesh：

Substances：

Year:  2017        PMID： 29174186     DOI： 10.1016/j.jgo.2017.11.003

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN： 1879-4068            Impact factor:   3.599


× No keyword cloud information.
  5 in total

1.  Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.

Authors:  Guido Giordano; Antonio Febbraro; Erica Quaquarini; Anna Turletti; Rebecca Pedersini; Mimma Raffaele; Federica Villa; Rosalba Rossello
Journal:  Oncology       Date:  2018-07-24       Impact factor: 2.935

Review 2.  Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios.

Authors:  Laura Pizzuti; Eriseld Krasniqi; Giacomo Barchiesi; Marco Mazzotta; Maddalena Barba; Antonella Amodio; Gioia Massimiani; Fabio Pelle; Ramy Kayal; Enrico Vizza; Antonino Grassadonia; Silverio Tomao; Aldo Venuti; Teresa Gamucci; Paolo Marchetti; Clara Natoli; Giuseppe Sanguineti; Gennaro Ciliberto; Patrizia Vici
Journal:  J Cancer       Date:  2019-10-12       Impact factor: 4.207

3.  Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.

Authors:  Kenji Tsuchihashi; Hitoshi Kusaba; Tomoyasu Yoshihiro; Toshifumi Fujiwara; Nokitaka Setsu; Makoto Endo; Yoshihiro Matsumoto; Takashi Imajima; Yudai Shinohara; Mamoru Ito; Satoru Yamaga; Kenro Tanoue; Kohei Arimizu; Hirofumi Ohmura; Fumiyasu Hanamura; Kyoko Yamaguchi; Taichi Isobe; Hiroshi Ariyama; Yasuharu Nakashima; Koichi Akashi; Eishi Baba
Journal:  Sci Rep       Date:  2020-12-01       Impact factor: 4.379

4.  Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.

Authors:  Milana Bergamino Sirvén; Adela Fernández-Ortega; Agostina Stradella; Idoia Morilla; Catalina Falo; Silvia Vázquez; Roser Castany; Rafael Villanueva; Sabela Recalde; Valentí Navarro Pérez; Miguel Gil-Gil; Sonia Pernas
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-21       Impact factor: 2.483

5.  Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.

Authors:  Yannan Zhao; Ning Xie; Wei Li; Wenyan Chen; Zheng Lv; Yabing Zheng; Tao Sun; Jieqiong Liu; Jian Zhang; Shihui Hu; Yajun Wang; Chengcheng Gong; Yi Li; Yizhao Xie; Rui Ge; Fei Xu; Biyun Wang
Journal:  Ther Adv Med Oncol       Date:  2021-07-09       Impact factor: 8.168
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.